You are here

Research

What ‘100 Percent Effective’ Means for That Ebola Vaccine

Analysis
WIRED.COM by Katie M. Palmer                                                            Aug. 4, 2015

Last week, the medical journal the Lancet published preliminary results on the efficacy of an Ebola vaccine in Guinea, and everybody got really excited—especially about one particular figure. The vaccine, the results suggested, was 100 percent effective at protecting against Ebola, a thrilling prospect in the face of an epidemic that has killed more than 11,000 people. ...

But that number probably means less than you think it does. It’s based on incomplete data, so it doesn’t have the statistical clout it should. And it never will. Based on the vaccine’s early success, the trial’s runners decided that all participants in the study should get it immediately after exposure. That’s a perfectly reasonable, humane reaction, but it also means that the researchers will never be able to collect better data on the vaccine’s efficacy, which is what regulators look for when they’re deciding to approve a drug. In other words, the vaccine’s early success could make it harder for people to get it down the line.

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

The Individualised versus the Public Health Approach to Treating Ebola

PLOS/Medicine   by  Tom H. Boyles                            July 28, 2015

The mortality rate for patients with Ebola virus disease (EVD) in West Africa is approximately 65% [1]. There are no published figures for high-resource settings, but media sources and individual case reports suggest it is much lower and approaches 0% for those who receive this level of care from the beginning of their illness.

In their article “Ebola Viral Disease: Experience and Decision Making for the First Cases outside of Africa,” David Stephens and colleagues give insight into the care that can be provided when available resources are not the limiting factor [2]. They describe the decision to open the Serious Communicable Diseases Unit (SCDU) of Emory University Hospital (EUH) when two United States patients contracted EVD while working in West Africa. Using a large specialist team, they provided high-quality care in a safe working environment and disseminated their knowledge and experience widely.....

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Addressing therapeutic options for Ebola virus infection in current or future outbreaks

AMERICAN SOCIETY FOR MICROBIOLOGY  by Azizul Haque and others                                July  27, 2015

 Ebola virus can cause severe hemorrhagic disease with high fatality rates. Currently, no specific therapeutic or vaccine has been approved for treatment and prevention of Ebola infection of humans. Although the number of Ebola cases has fallen in the last few weeks, multiple outbreaks of Ebola virus infection and the likelihood of future exposure highlight the need for development and rapid evaluation of pre- and post-exposure treatments.

In this manuscript we briefly review the existing and future options for anti-Ebola therapy, based on the data coming from rare clinical reports, studies on animals and results from in vitro models....

Read complete report

http://aac.asm.org/content/early/2015/07/21/AAC.01105-15.short?rss=1

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Ebola study notes afebrile patients, calls into question WHO criteria

CENTER FOR DISEASE RESEARCH AND POLICY        July 24, 2015

(Also scroll down for: Ebola case definition quandary; Public health worker Ebola unease)

Researchers found that the World Health Organization (WHO) Ebola case definition has a specificity of only 31.5%, and they noted that 9% of Ebola patients reported neither a fever nor any Ebola risk exposure, calling into question WHO norms, according to a large study yesterday in The Lancet Infectious Diseases.

Researchers from Britain and Sierra Leone analyzed data on 850 suspected and 724 lab-confirmed Ebola patients who presented to the holding unit of Connaught Hospital in Freetown from May 29 to Dec 8, 2014. Fever or history of fever (n=599, 83%), intense fatigue or weakness (495, 68%), vomiting or nausea (365, 50%), and diarrhea (294, 41%) were the most common presenting symptoms in suspected cases.

Based on data from these patients, the investigators found the sensitivity of the WHO case definition to be 79.7%, which means about 20% of true Ebola cases would be missed (false-negatives). They found the specificity of the case definition to be 31.5%, which means 68.5% of patients who would be selected for admission would not actually have Ebola virus disease (false-positives).

Read complete story.

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Experimental Ebola drug shelved; study explores virus clearance

CENTER FOR INFECTIOUS DISEASE POLICY AND RESEARCH by Lisa Schnirring     July 20, 2015

Tekmira Pharmaceuticals  announced that it has suspended development of TKM-Ebola, a drug cocktail that showed disappointing human trial results in West Africa, as a convalescent plasma trial at a Doctors Without Borders (MSF) facility in Guinea proceeded with no ill effects in patients so far...

In suspending TKM-Ebola development, the company said that a joint reevaluation of its contract with the US Department of Defense is under way.

In another development, MSF said a convalescent serum trial at its facility in Nongo, Guinea, has enrolled 101 people over the last few months, with no ill effects reported so far, according to a Jul 17 update on the outbreak. Patients at the Nongo treatment unit have the option to receive plasma donated by Ebola survivors....

Meanwhile, detailed testing at a Swiss hospital on a 43-year-old doctor infected with Ebola in Sierra Leone found that viral decay occurred in two phases, once starting 72 hours after symptom onset before any antiviral interventions, with acceleration in viral load decay after ZMAb infusion and oral favipiravir treatments began..

Read complete article.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Research Data Alliance Outputs

A publication, more deeply explaining the Reasearch Data Alliance (RDA) and it's outputs.

Meeting / Event Tags: 
Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

RDA Presentation

A presentation given by Dr. Francine Berman, a professor at RPI in new York to the National Information Technolgy Research and Development (NITRD) organization on July 15, 2015. The briefing outlines the purpose, mission and objectives of the International Reserach Data Alliance (RDA). Dr. Berman heads the U.S. RDA initiative. The briefing is entitled "Building Community and Infrastructure for data Sharing Worldwide".

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Group Six Deliberation Notes

Upon selection the "Read More" button below, an attachment becomes evident. This attached file contains the notes from the Group Six deliberations on "Sense-making and Situational Awareness" during the Working Meeting on July 8 at One UN Plaza in New York City. These notes were recompiled from rough notes taken at the meeting nearly a week later and may need revision. Please offer observations, comments or potential corrections using the comments capability below.

Meeting / Event Tags: 
Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Notes from 8 July Working Session in NYC

Upon selection the "Read More" button below, an attachment becomes evident. This attached file contains the notes from all the public presntations delivered during the Working Meeting on July 8 ay One UN Plaza in New York City. Please offer observations, comments or potential corrections using the comments capability below.

Meeting / Event Tags: 
Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Revised Arresting Ebola Briefing

Link to the Revised Arresting Ebola IT Briefing in a separate window on a remote host. This briefing is a revised version of the original Arresting Ebola IT Briefing, based on the outcome of Group 6 at the UN Ebola Event on 8 July 2015 in New York City. Please feel free to comment or offer change suggestions using the comments capability below.

Meeting / Event Tags: 
Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Research
howdy folks